https://www.selleckchem.com/products/rmc-7977.html
The mean adjusted eGFR slope during TDF and TAF exposure was -2.08 [95% confidence interval (CI) -2.24, -1.92] and 1.18 (95% CI 0.20, 1.52) mL/min/1.73m /year, respectively (P0.001). Individuals who experienced rapid eGFR decline (3 or 5mL/min/1.73m /year) while receiving TDF experienced significant eGFR recovery while on TAF (P0.001). Significant improvement in eGFR slope was observed in patients who switched from TDF- to TAF-containing antiretroviral regimens. These data provide further support for the renal safety of TAF